13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001910264
Total reported value
$1.0B
$1.0B
14 檔
66.0%
According to the latest 13F quarterly dataset, Sr One Capital Management, LP managed an equity portfolio of $1.0B at the end of Q1 2026, spanning 14 distinct U.S. exchange-listed positions.
In Q1 2026, Sr One Capital Management, LP displayed an active expansion posture, initiating 1 new positions and adding to 0 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including ACLXGBX, MANE, ZBIO) accounted for 66.0% of total reported equity market value during Q1 2026.
Top New Position Initiated
MANE
市值: $151.7M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ACLXGBX | Arcellx Inc | Stock-Other | 29.43% | -29.43% | EXIT | |
| 2 | MANE | Veradermics Inc | Stock-Other | 16.57% | +11.85% | — | |
| 3 | ZBIO | Zenas Biopharma Inc | Stock-Other | 10.76% | +1.55% | — | |
| 4 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 10.59% | +0.11% | — | |
| 5 | DSGN | Design Therapeutics Inc | Stock-Other | 7.59% | +1.50% | — | |
| 6 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 6.39% | -1.58% | — | |
| 7 | ALMS | Alumis Inc | Stock-Other | 4.72% | +0.59% | — | |
| 8 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 4.63% | -0.57% | — | |
| 9 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 3.52% | -0.43% | — | |
| 10 | ORKA | Oruka Therapeutics Inc | Stock-Other | 2.31% | -2.31% | EXIT | |
| 11 | OCS | Oculis Holding AG | Stock-Other | 1.86% | -1.00% | — | |
| 12 | NKTX | Nkarta Inc | Stock-Other | 0.77% | +0.14% | — | |
| 13 | ✓ | Engene Holdings Inc | Stock-Other | 0.56% | -0.44% | — | |
| 14 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.32% | +0.12% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ACLXGBX | Arcellx Inc | +7.8% | — | Unchanged |
| 2 | ALMS | Alumis Inc | +2% | — | Unchanged |
| 3 | ORIC | Oric Pharmaceuticals Inc | +1.1% | — | Unchanged |
| 4 | ORKA | Oruka Therapeutics Inc | +0.5% | — | Unchanged |
| 5 | OCS | Oculis Holding AG | +0.1% | — | Unchanged |
| 6 | NKTX | Nkarta Inc | -0.1% | — | Unchanged |
| 7 | RARE | Ultragenyx Pharmaceutical In | -0.1% | — | Unchanged |
| 8 | ✓ | Engene Holdings Inc | -0.4% | — | Unchanged |
| 9 | DSGN | Design Therapeutics Inc | -1.1% | — | Unchanged |
| 10 | SPRY | Ars Pharmaceuticals Inc | -3.1% | — | Unchanged |
| 11 | MLYS | Mineralys Therapeutics Inc | -3.4% | — | Unchanged |
| 12 | CRSP | CRISPR Therapeutics AG | -4.6% | — | Unchanged |
| 13 | ZBIO | Zenas Biopharma Inc | -15.1% | — | Unchanged |
| 14 | MANE | Veradermics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Sr One Capital Management, LP reported a total U.S. public equity portfolio value of $1.0B across 14 disclosed positions in Q1 2026.
During Q1 2026, Sr One Capital Management, LP's top holdings by market value included ACLXGBX (29.4%)、MANE (16.6%)、ZBIO (10.8%). The largest single position, ACLXGBX, represented 29.4% of total portfolio value.
In Q1 2026, Sr One Capital Management, LP made 1 total portfolio adjustments, initiating 1 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.